https://legaldesire.com/latham-watkins-advises-seres-therapeutics-in-vowst-asset-purchase-agreement-with-nestle-health-science/
Latham & Watkins Advises Seres Therapeutics in VOWST Asset Purchase Agreement With Nestlé Health...
Aug 7, 2024 - Multidisciplinary team represents the commercial biotechnology company in the transaction. Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres...
asset purchase agreementlatham watkinsseres therapeuticsadvisesvowst
https://markets.financialcontent.com/dailypennyalerts/quote/news?CurrentPage=4&Symbol=NQ%3AMCRB
Daily Penny Alerts - Latest News about Seres Therapeutics, Inc. - Common Stock (Nasdaq:MCRB) |...
latest newsseres therapeuticscommon stockdailypenny
https://www.flagshippioneering.com/news/press-release/seres-therapeutics-announces-microbiome-immuno-oncology-focused-collaboration-with-astrazeneca
Seres Therapeutics Announces Microbiome… | Flagship Pioneering
Flagship Pioneering is a a biotechnology company that invents platforms and builds companies that change the world.
seres therapeuticsflagship pioneeringannounces
https://www.businesswire.com/news/home/20231006105161/en/Seres-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on October 4, 2023, the C...
seres therapeuticsreportsinducementgrantsnasdaq